Released: 9/10/2009
Expires: 9/10/2010

Target Audience
This activity was developed for oncology nurses and pharmacists who wish to enhance their knowledge concerning the treatment of patients with T-cell lymphomas.

Learning Objectives
At the completion of this activity participants should be able to:

• Describe standard treatment strategies for patients with cutaneous T-cell lymphomas (CTCLs) and peripheral T-cell lymphomas (PTCLs), in both the first-line and relapsed/refractory settings
• Discuss safety and efficacy data as it pertains to novel agents being used to treat CTCL and PTCL
• Identify common adverse events associated with novel therapies for CTCL and PTCL and discuss appropriatemanagement strategies

Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider 15106, for 1.0 contact hour.

Registered Pharmacy Designation
Medical Learning Institute (MLI) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.0 contact hour (0.1 CEU) of continuing education credit. The universal program number for this activity is 468-999-09-024-H01-P

Instructions for Credit
There is no fee for this activity. To receive credit, participants must first take the pretest for this activity. After reading this CE activity in its entirety, participants must complete the posttest and evaluation. The pretest, posttest, and evaluation can be completed online at www.mlicme.org/p09035.html. Upon completion of the evaluation and scoring a 70% or better on the posttest, you will immediately receive your certificate online. If you do not achieve a score of 70% or better on the posttest, you will be asked to take it again. Please retain a copy of the Certificate for your records.

For questions regarding the accreditation of this activity, please contact Medical Learning Institute at (609) 333-1693 or cgusack@mlicme.org.

Disclosure Statement
Before the activity, all faculty will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial products(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.

The associates of Medical Learning Institute, Inc. have no financial relationships to disclose. The associates of Center of Excellence Media, LLC, have no financial relationships to disclose.

Faculty Disclosures
Gary C. Yee, PharmD, FCCP, BCAP, is on the Advisory Board of Amgen and Eisai. He discusses bendamustine, bortezomib, ofatumumab, and temsirolimus.

Robin Gemmill, RN, MSN, CNS, CWOCN has nothing to disclose.


*Content will include non-FDA-approved uses.

Disclaimer
The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.